BioCentury | May 2, 2020
Translation in Brief

ORIC’s CD73 inhibitor for cancer; plus Beam, CRISPR-Cas13 for respiratory infections, COVID-19 complex structure, and more

Small molecule CD73 inhibitor for cancer   A small molecule CD73 inhibitor from ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) has shown significant antitumor activity in vivo . ORIC-533 is slated for an IND submission in 1H21. CD73, which...
BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

Migraine drug marks Biohaven’s first FDA approval Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) announced after market close that FDA approved NURTEC ODT rimegepant as an acute treatment for migraine, marking the company’s first U.S. approval....
BC Extra | Jan 27, 2020
Company News

AZ regains brazikumab rights as AbbVie paves way for closure of $63B takeout of Allergan

AstraZeneca is regaining a late-stage immunology program from Allergan in a deal designed to clear the way for U.S. and EU regulators to approve AbbVie’s $63 billion takeover of Allergan. AstraZeneca plc (LSE:AZN; NYSE:AZN) told...
BC Extra | Dec 6, 2019
Clinical News

Biogen Alzheimer’s data won’t sway believers or doubters either way

The upshot of Biogen’s aducanumab data is that the robustness of the compound’s efficacy remains in doubt. The CTAD presentation gave enough grist for believers to continue believing and skeptics to keep on doubting. Aducanumab...
BC Innovations | Nov 18, 2019
Distillery Therapeutics

Tyrosine kinase inhibitors for the treatment of pemphigus

DISEASE CATEGORY: Autoimmune disease INDICATION: Pemphigus Tyrosine kinase inhibitors including the dual BCR-ABL/c-Kit inhibitor imatinib could treat pemphigus, an autoimmune blistering disorder. Pemphigus is caused by antibodies against the keratinocyte adhesion molecule DSG3. Imatinib reduced...
BC Extra | Sep 30, 2019
Company News

Sobi adding to U.S. presence, hematology pipeline via $915M Dova takeout

With the $915 million takeout of Dova Pharmaceuticals and a co-development deal with Sanofi in hemophilia, Sobi is continuing its push into the U.S. and strengthening its presence in hematology. Swedish Orphan Biovitrum AB (SSE:SOBI)...
BC Extra | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

Aridis discontinuing antibacterial mAb   Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) said AR-105 plus standard of care antibiotics missed the primary endpoint of superiority to antibiotics alone in a Phase II trial to treat ventilator-associated pneumonia (VAP)...
BC Extra | Aug 26, 2019
Company News

With Celgene's $13.4B sale of Otezla, Amgen adds to anti-inflammatory franchise

Investors appeared to be more than satisfied with Celgene's take from the sale of Otezla to Amgen for $13.4 billion in cash, removing a hurdle from BMS's path toward the completion of its proposed $74...
BC Innovations | Aug 22, 2019
Distillery Therapeutics

TNFR2 agonism for neuropathic pain

DISEASE CATEGORY: Neurology INDICATION: Pain TNFR2 agonism could help treat neuropathic pain. TNFR2 activity has implicated in early development of neuropathic pain as well as the promotion of anti-inflammatory responses thought to suppress development of...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
Items per page:
1 - 10 of 1085